The study aim is to perform a retrospective chart review of liver enzyme values in pediatric patients taking Trikafta, a medication for cystic fibrosis. Recently, monitoring recommendations from Health Canada have changed and children will have to undergo double the amount of blood testing when initiating therapy. The evidence to support this recommendation is weak and it is our goal to demonstrate that the incidence of drug-induced liver injury is low in a real-life cohort. It is our vision is that a child or youth with CF and/or their family will serve as a consultant for the protocol and final manuscript. We would work with the patient/family to identify outcomes of interest to them and their experience. They would also be included as an author on the manuscript, contributing to study design (outcomes) and the article discussion.
Eligibility
Participant must be a patient with CF attending the IWK CF Clinic or a caregiver/family member of a child with CF.
Time Commitment
The engagement will start in Spring 2026 and continue until manuscript publication (hopefully by December 2026). Approximately 3-5 hours will be required for meetings as well as 3-5 hours of offline work on the participant’s own schedule.
Compensation
Authorship on study publications (manuscripts and posters).